Expression pattern of a hematopoietic proteoglycan core protein gene during human hematopoiesis.
Expression of the hematopoietic proteoglycan core protein (HpPG) gene was examined in normal peripheral blood, normal bone marrow, and leukemic peripheral blood leukocytes samples to assess the expression pattern of the HpPG gene in these cells and to ascertain points of regulation of this gene during hematopoiesis. In situ hybridization to normal bone marrow and peripheral blood leukocytes demonstrated that the gene was expressed in the promyelocytes at a approximately two fold greater level than in the segmented neutrophils and the expression decreased as the granulocytes matured. The ratio of expression in the other leukocytes to expression in the segmented neutrophils were as follows: eosinophils/basophils approximately 7; monocytes approximately 2; lymphocytes less than 1. Expression of the HpPG gene during myeloblast differentiation was assessed by Northern blot analysis of acute myelogenous leukemia (AML) RNA samples. The expression of this gene, when compared to the levels in HL-60 cells, was approximately ten fold lower in the poorly differentiated blast cells obtained from three AML patients classified M"0". Conversely, the expression in the more differentiated blast cells obtained from 10 of 11 AML patients classified as M1 and M2 were at levels similar to the levels in HL-60 cells. The expression level found in eight lymphoid leukemias was approximately ten fold or more lower than in HL-60 cells. Gene copy number determination confirmed that the HpPG gene is present in one copy per haploid genome. Thus the HpPG gene's expression pattern denotes a single copy gene being differentially expressed during hematopoiesis with initial regulation occurring very early in this developmental process and an additional up-regulatory event occurring during granule genesis.
Stellrecht
C M
CM
Department of Biochemistry and Molecular Biology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Mars
W M
WM
Miwa
H
H
Beran
M
M
Saunders
G F
GF
D053674:Aggrecans; D015152:Blotting, Northern; D001853:Bone Marrow / Q000378:metabolism; D001854:Bone Marrow Cells; D002478:Cells, Cultured; D016326:Extracellular Matrix Proteins; D005786:Gene Expression Regulation / Q000235:genetics*; D015973:Gene Expression Regulation, Leukemic / Q000235:genetics*; D006023:Glycoproteins / Q000235:genetics*; D006410:Hematopoiesis / Q000235:genetics*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D016130:Immunophenotyping; D037181:Lectins, C-Type; D007945:Leukemia, Lymphoid / Q000235:genetics; D007951:Leukemia, Myeloid / Q000473:pathology; D007962:Leukocytes / Q000166:cytology / Q000378:metabolism; D005810:Multigene Family / Q000235:genetics; D009504:Neutrophils / Q000166:cytology / Q000378:metabolism; D011509:Proteoglycans; D012313:RNA / Q000235:genetics; D014407:Tumor Cells, Cultured / Q000378:metabolism / Q000473:pathology
D053674:Aggrecans; D016326:Extracellular Matrix Proteins; D006023:Glycoproteins; D037181:Lectins, C-Type; D011509:Proteoglycans; D012313:RNA